Merck announces Molnupiravir reduced risk of death at a planned interim analysis of its Phase 3 trial 0 02.10.2021 15:58 The Financial Express Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
